Spyre Therapeutics Inc (NAS:SYRE)
$ 36.93 1.74 (4.94%) Market Cap: 1.49 Bil Enterprise Value: 1.26 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 34/100

Aeglea Bio Therapeutics Inc at Guggenheim Securities Inflammation & Immunology Conference Transcript

Nov 07, 2023 / NTS GMT
Release Date Price: $10.06 (-5.98%)
Yatin Suneja
Guggenheim Partners - Analyst

Good morning, everyone. Myself, Yatin Suneja. I'm one of the biotech analysts here at Guggenheim. It is my pleasure to welcome each one of you at our fifth annual I&I conference. This is day two.

Our first presenting company for the day is Spyre. From the company, we have Cameron Turtle, who is the Chief Operating Officer. It's a relatively newer company. Recent reverse merger or the reverse merger is in the process right now.

I will hand it over to Cameron maybe to just give us an overview of the company, just talk about the founding of the company, what are some of the key up-and-coming milestones. Maybe spend five minutes on that, and then I have a set of questions that I want to run through.

So Cameron, that's all yours.

Cameron Turtle
Aeglea BioTherapeutics, Inc. - COO

All right. Thanks, Yatin, and thanks for having us. Thanks, everyone, for the time this morning.

So as you mentioned, we just launched Spyre earlier this year. And I think, really, the goal here -- it's a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot